Teva Pharmaceuticals has increased its 2026 U.S. sales forecast for Uzedy, an injectable schizophrenia treatment, following better-than-expected Q3 2026 sales. This upward revision signals strong market adoption and potential for continued growth for the product, positively impacting Teva and its partner MedinCell.
Teva Pharmaceuticals has raised its 2026 U.S. sales forecast for Uzedy, an injectable schizophrenia treatment, for the second time this year. This revision comes after Uzedy's Q3 2026 net sales of $85 million significantly beat analyst consensus of $74 million, indicating stronger-than-anticipated market penetration and demand. This is a positive development for Teva, as it suggests a key product is performing well and contributing more to future revenue than previously expected. For MedinCell, the developer, it means higher royalty payments and potential for additional milestone payments, directly benefiting its financial outlook. The short-term implication is a potential boost in investor confidence for both companies, while long-term, it reinforces Uzedy's position as a significant revenue driver. The key opportunity for traders lies in the sustained growth trajectory of Uzedy and its positive impact on Teva's overall financial health.